(R)-AS-1
Based on 1 Customer Validation
(R)-AS-1 is an orally active EAAT2 enhancer that crosses the blood-brain barrier. (R)-AS-1 enhances EAAT2-mediated glutamate uptake by increasing the transport rate without altering substrate affinity. (R)-AS-1 can be used for research on epilepsy.
For research use only. We do not sell to patients.
- Purity : 99.9%
- CAS No.: 2506367-95-7
- Formula: C14H16N2O3
- Molecular Weight:260.29
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
EAAT2 11 nM (EC50) |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
In Vivo
(R)-AS-1 protects mice against 6 Hz 32 mA psychomotor seizures with an i.p. ED50 of 15.6 mg/kg[1].
(R)-AS-1 protects mice against 6 Hz 44 mA drug-resistant psychomotor seizures, with an i.p. ED50 of 41.6 mg/kg[1].
(R)-AS-1 protects mice against scPTZ-induced seizures with an i.p. ED50 of 36.3 mg/kg, and prolongs seizure latency at doses of 40 and 60 mg/kg[1].
(R)-AS-1 (p.o.) protects mice against MES-induced tonic convulsions, with an ED50 of 48.6 mg/kg[1].
(R)-AS-1 (p.o.) protects mice against 6 Hz 32 mA psychomotor seizures, with an ED50 of 40.3 mg/kg[1].
(R)-AS-1 (p.o.) protects mice against 6 Hz 44 mA drug-resistant psychomotor seizures, with an ED50 of 73.2 mg/kg[1].
(R)-AS-1 (p.o.) protects mice against scPTZ-induced convulsions with an ED50 of 83.5 mg/kg, and prolongs convulsion latency at doses of 80 and 100 mg/kg[1].
(R)-AS-1 (10-40 mg/kg; i.p.; three times per week; 21 PTZ injections) delays the progression of PTZ kindling in mice at a dose of 40 mg/kg[1].
(R)-AS-1 (1-4 mM; incubation; 24 h) reduces PTZ-induced electrographic seizure events in zebrafish larvae at a concentration of 4 mM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:albino Swiss (male, naïve)[1]
-
Dosage:10, 20, and 40 mg/kg
-
Administration:i.p.; 30 min before each PTZ injection; three times weekly for 21 PTZ injections
-
Result:At 10 and 20 mg/kg, decreased the mean seizure severity score after the 9th and 14th PTZ injections.
At 40 mg/kg, delayed kindling progression, with reduced mean seizure severity scores after the 12th, 14th, and 18th-21st PTZ injections.
In the 40 mg/kg group, the mean seizure severity score was 0.75 after the first PTZ injection and 2.5 after the last PTZ injection.
Chemical Information
-
CAS No. 2506367-95-7
-
Appearance Solid
-
Molecular Weight 260.29
-
Formula C14H16N2O3
-
Color Off-white to light yellow
-
SMILES
O=C(NCC1=CC=CC=C1)[C@H](N2C(CCC2=O)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)